Form 4: Bioxytran Director Alan Hoberman Executes Stock Conversion

Director Alan Hoberman converted common stock into convertible preferred stock in a 5:1 exchange.

Summary

• On August 16, 2024, Alan Hoberman, a director of Bioxytran, Inc., acquired 123,967 shares of common stock at $0.121 per share.
• On August 19, 2024, Hoberman disposed of 1,133,389 shares of common stock at $0.159 per share.
• On August 19, 2024, Hoberman acquired 226,678 shares of preferred stock at $0.795 per share.
• The transactions involved a 5:1 exchange of common stock into convertible preferred stock, with a conversion ratio of 1:5 shares into common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency into the trading activities of company directors. It's important for investors to monitor such filings to understand the sentiment and actions of company insiders.

Stakeholder Impact

• Shareholders may be interested in the director's decision to convert common stock to preferred stock, as it could signal a change in investment strategy or expectations for the company's future performance.

Key Dates

Keywords

Bioxytran, Director, Alan Hoberman, Stock Conversion, Preferred Stock, Common Stock, Form 4, Insider Trading